On the interaction between phenytoin and digoxin
- PMID: 4054206
- DOI: 10.1007/BF00547368
On the interaction between phenytoin and digoxin
Abstract
An open, randomized, single-blind cross over trial to investigate phenytoin-digoxin interactions at steady state was performed in 6 healthy male volunteers. Coadministration of phenytoin caused a significant reduction in the elimination half-life of digoxin from 33.9 to 23.7 h and a diminution in AUC0-48 from 31.6 to 24.4 ng X ml-1 X h. Renal digoxin clearance was not significantly altered from 135.7 to 120.3 ml X min-1. Assuming no change in beta-acetyldigoxin absorption, the in decrease time-course the serum digoxin concentration was due to a significantly increased total digoxin clearance from 258.6 to 328.3 ml X min-1. An insignificant reduction in the digoxin distribution volume from 749.4 to 668.0 l was also observed. No relevant change in the pharmacokinetic parameters (elimination half-life, area under the serum concentration time-curve, protein binding) of phenytoin was observed when phenytoin and digoxin were co-administered. The data suggest that with this drug combination the serum digoxin concentration should be carefully monitored and, if necessary, the daily digoxin dose should be increased.
Similar articles
-
Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered?Int J Clin Pharmacol Ther Toxicol. 1985 Mar;23(3):145-53. Int J Clin Pharmacol Ther Toxicol. 1985. PMID: 3997300 Clinical Trial.
-
The effect of phenytoin on the tissue concentrations of digoxin in the rat.Acta Pharmacol Toxicol (Copenh). 1977 Nov;41(5):481-8. doi: 10.1111/j.1600-0773.1977.tb02159.x. Acta Pharmacol Toxicol (Copenh). 1977. PMID: 579559
-
The diltiazem-digoxin interaction.Clin Pharmacol Ther. 1984 Aug;36(2):183-9. doi: 10.1038/clpt.1984.160. Clin Pharmacol Ther. 1984. PMID: 6744777 Clinical Trial.
-
Current status of cardiac glycoside drug interactions.Clin Pharm. 1985 Jul-Aug;4(4):404-13. Clin Pharm. 1985. PMID: 2412751 Review.
-
Clinical pharmacokinetics of mizolastine.Clin Pharmacokinet. 2001;40(7):501-7. doi: 10.2165/00003088-200140070-00002. Clin Pharmacokinet. 2001. PMID: 11510627 Review.
Cited by
-
The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?Clin Pharmacokinet. 2002;41(4):235-53. doi: 10.2165/00003088-200241040-00001. Clin Pharmacokinet. 2002. PMID: 11978143 Review.
-
Antiepileptic drugs. A review of clinically significant drug interactions.Drug Saf. 1993 Sep;9(3):156-84. doi: 10.2165/00002018-199309030-00003. Drug Saf. 1993. PMID: 8240723 Review.
-
Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours.Br J Clin Pharmacol. 2020 Apr;86(4):771-778. doi: 10.1111/bcp.14178. Epub 2020 Jan 7. Br J Clin Pharmacol. 2020. PMID: 31770456 Free PMC article.
-
Herb-drug interactions: a literature review.Drugs. 2005;65(9):1239-82. doi: 10.2165/00003495-200565090-00005. Drugs. 2005. PMID: 15916450 Review.
-
Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies.Clin Pharmacokinet. 2020 Jun;59(6):699-714. doi: 10.1007/s40262-020-00867-1. Clin Pharmacokinet. 2020. PMID: 32052379 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous